ArticleNature2022
STING-induced regulatory B cells compromise NK function in cancer immunity.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers.
0numbers the graph read from it
0cells of the map it votes in
218citing papers in PubMed
22.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
218 citing papers in PubMed, 292 citations in OpenAlex.
- Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial.Nature medicine · 2026Trial
- An engineered bacteria-chitosan hybrid robot for lactate depletion and synergistic STING activation to potentiate bladder cancer immunotherapy.Materials today. Bio · 2026Article
- The cGAS-STING/MITA pathway in innate antiviral immunity and beyond.Cell insight · 2026Review
- Article
- IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4Journal for immunotherapy of cancer · 2026Article
- The bidirectional immunoregulatory effects of Traditional Chinese Medicine on the cGAS-STING signaling pathway and their translational prospects.Chinese medicine · 2026Review
- Radiation-induced CD200Cellular & molecular immunology · 2026Article
- Enhanced antitumor immunity of mRNA vaccines by bioorthogonal-like delayed activation of exogeneous STING.Nature biotechnology · 2026Article
- The cGAS/STING pathway in cancer: translating innate DNA sensing into therapeutic potential.The Journal of clinical investigation · 2026Review
- Amine oxide lipid nanoparticles for delivery of cyclic dinucleotides.National science review · 2026Article
- Nucleotide Metabolism in Health and Disease.MedComm · 2026Review
- Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models.Cell reports. Medicine · 2026Article
- Dendritic cell redundancy enables priming of anti-tumor CD4Cancer cell · 2026Article
- The diversity of STING in regulating immune cell function and its role in liver diseases: from bench to bedside.Cell & bioscience · 2026Review
- Review
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Tumor infiltrating B cells and tertiary lymphoid structures in pancreatic cancer prognosis and therapy.iScience · 2026Review
- EngineeredMolecular therapy. Oncology · 2026Article
- A neutrophil-tumor cascade-targeting Trojan horse for heterobifunctional prodrug delivery to enhance cGAS-STING cancer immunotherapy.Journal of nanobiotechnology · 2026Article
- B10 Adoptive Transfer Ameliorates Inflammation and Bone Loss in Experimental Periodontitis Through Promoting Macrophage-Mediated Pro-Resolving Functions.Inflammation · 2026Article
158 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Sirui Li *Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-1645-6868
Bhalchandra Mirlekar *Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Brandon M JohnsonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-3871-3378
W June BrickeyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
John A WrobelLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-5828-9359
Na YangFunctional Epigenomics Unit (HNN-2G5), National Institute on Aging, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3292-7156
Dingka SongLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-8481-9309
Sarah EntwistleLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-9322-1288
Xianming TanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-5478-2269
Meng DengLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-9051-7534
Ya CuiDivision of Computational Biomedicine, Department of Biological Chemistry, School of Medicine, University of California, Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0003-1574-0928
Wei LiDivision of Computational Biomedicine, Department of Biological Chemistry, School of Medicine, University of California, Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0001-9931-5990
Benjamin G VincentLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-1762-2282
Michael GaleDepartment of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6332-7436
Yuliya Pylayeva-GuptaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. yuliyap1@email.unc.edu.ORCID http://orcid.org/0000-0003-4458-9091
Jenny P-Y TingLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. jenny_ting@med.unc.edu.ORCID http://orcid.org/0000-0002-7846-0395
University of North Carolina at Chapel Hill · USUniversity of California, Irvine · USNational Institute on Aging · USUniversity of Washington · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MSomatostatin analogues as countermeasures against intestinal radiation toxicityU19AI067798 · NIAID · DUKE UNIVERSITY · PI DOAN, PHUONG LINH · 2005 to 2024
$82.1MUnlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MCWEENEY, SHANNON K. · 2012 to 2021
$36.6MWashington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9MIntracellular Innate Immune Receptors in Cancer Suppression and ImmunotherapyR35CA232109 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TING, JENNY P · 2019 to 2025
$6.4MMolecular and Functional Analysis of NLR Family MembersR01AI029564 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jenny P Ting · 1991 to 2026
$6.0MFunction of IL35+ B cells in pancreatic cancerR37CA230786 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PYLAYEVA-GUPTA, YULIYA · 2019 to 2025
$3.0MNCI NIH HHS P30 CA016086NCI NIH HHS P50 CA196510NCI NIH HHS R35 CA232109NCI NIH HHS R37 CA230786NIAID NIH HHS R01 AI029564NIAID NIH HHS U19 AI067798NIAID NIH HHS U19 AI100625
Abstract
An immunosuppressive tumour microenvironment is a major obstacle in the control of pancreatic and other solid cancers
Indexed as
B-Lymphocytes, RegulatoryKiller Cells, NaturalNeoplasmsAnimalsHumansImmunity, InnateImmunotherapyInterferon Regulatory Factor-3Interferon Type IInterleukinsMembrane ProteinsMiceNucleotides, CyclicSTING ProteinTumor Microenvironmentcyclic guanosine monophosphate-adenosine monophosphateInterferon Regulatory Factor-3Interferon Type Iinterleukin-35, humaninterleukin-35, mouseInterleukinsMembrane ProteinsNucleotides, CyclicSTING1 protein, humanSting1 protein, mouseSTING Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.